SCHEMBL18713571

SCHEMBL18713571

CCC(C)c1ccc(Cl)cc1-c1ccc2ccccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.44
▸ GSTP1 P09211 1/20 0.40
▸ AKR1C3 P42330 3/20 0.39
▸ AKR1C2 P52895 3/20 0.39
▸ SELPLG Q14242 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CMA1 P23946 1/20 0.36
▸ CDC25A P30304 1/20 0.36
▸ CDC25B P30305 1/20 0.36
▸ CDC25C P30307 1/20 0.36
▸ DUSP3 P51452 1/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ AR P10275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20032502 0.87 CYP2A6 (0.46) CYP2A6GSTP1AKR1C3AKR1C2CNR1
SCHEMBL18713960 0.82 CHRM1 (0.38) SELPLGTSHRIDO1CYP1A2
SCHEMBL20032156 0.78 MAPT (0.39) AKR1C3AKR1C2SELPLGCNR1IDO1
SCHEMBL18713646 0.78 MAPT (0.39) AKR1C3AKR1C2SELPLGCNR1IDO1
SCHEMBL18713787 0.78 PTGS2 (0.40) TSHR
SCHEMBL21507819 0.77 PTGS2 (0.38) SELPLGSLC6A4
SCHEMBL18713542 0.75 MRGPRX4 (0.38) SELPLGTSHR
SCHEMBL18713964 0.74 AKR1C3 (0.40) AKR1C3AKR1C2SLC6A4CYP1A2
SCHEMBL18713982 0.74 HTT (0.42) TSHRCYP1A2
SCHEMBL18713812 0.74 ALDH1A1 (0.35) AKR1C3AKR1C2SELPLGTSHRSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9750740-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors Kanos Pharmaceuticals, Inc. (US) 2017-09-05 — — US disclosed
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2017-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A CYP2A6 44/4885GSTP1 1312/4885AKR1C3 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback